Recombinant Artemisia vulgaris Artv1 Protein, N-His from ProteoGenix; catalogue ARO-P12699; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant proteins are proteins that are produced through genetic engineering techniques, allowing for the manipulation and expression of specific genes. One such recombinant protein is the Recombinant Artemisia vulgaris Artv1 Protein, which has gained attention for its potential therapeutic applications. In this article, we will explore the structure, activity, and potential applications of this protein.
The Recombinant Artemisia vulgaris Artv1 Protein is a 17.5 kDa protein that is composed of 158 amino acids. It is a member of the plant defensin family, which are small, cysteine-rich proteins that play a role in plant defense against pathogens. The protein has a three-dimensional structure consisting of a beta-sheet and an alpha-helix, which is stabilized by four disulfide bonds. This compact structure is essential for the protein’s stability and activity.
The Recombinant Artemisia vulgaris Artv1 Protein has been shown to have potent antimicrobial activity against a wide range of microorganisms, including bacteria, fungi, and viruses. This activity is due to the protein’s ability to disrupt the cell membrane of these pathogens, leading to their death. Additionally, the protein has been found to have anti-inflammatory and immunomodulatory properties, making it a potential candidate for treating inflammatory and autoimmune diseases.
The potential applications of Recombinant Artemisia vulgaris Artv1 Protein are vast, and ongoing research is being conducted to explore its therapeutic potential. One of the most promising applications is in the field of infectious diseases. The protein’s antimicrobial activity makes it a potential candidate for developing new antibiotics to combat drug-resistant bacteria. It has also shown promising results in treating fungal infections, such as candidiasis and aspergillosis.
Another potential application of Recombinant Artemisia vulgaris Artv1 Protein is in the treatment of inflammatory and autoimmune diseases. Studies have shown that the protein can inhibit the production of inflammatory cytokines and modulate the immune response, making it a potential candidate for diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Furthermore, the protein has also been studied for its potential in cancer treatment. It has been found to have cytotoxic effects on cancer cells, making it a potential candidate for developing new anticancer therapies. Additionally, the protein’s anti-inflammatory properties may also play a role in inhibiting tumor growth and metastasis.
The Recombinant Artemisia vulgaris Artv1 Protein is a promising protein with a compact structure and potent antimicrobial, anti-inflammatory, and immunomodulatory properties. Its potential applications in the fields of infectious diseases, inflammatory and autoimmune diseases, and cancer make it a valuable candidate for further research and development. With ongoing studies and advancements in genetic engineering techniques, this protein has the potential to revolutionize the treatment of various diseases.
ProteoGenix catalogue number ARO-P12699. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 13.09 kDa; Fragment: Ala25-His132; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
